Hearing aids are not proven to prevent Alzheimer's disease. They may help slow cognitive decline in some older adults at higher risk, but the strongest trial did not measure whether they prevented an Alzheimer's diagnosis. That distinction matters. Cognitive decline means worsening thinking or memory over time; Alzheimer's prevention means reducing new cases of the disease itself.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did the main trial test?
- Who appeared to benefit?
- Why hearing and brain health are connected—but not equivalent
- What should someone with hearing difficulty do now?
- What evidence is still missing?
What did the main trial test?
The ACHIEVE trial enrolled 977 dementia-free U.S. adults aged 70 to 84 who had untreated hearing loss. Researchers assigned them to hearing aids with audiologic support or to a health-education program, then followed them for three years.
Across all participants, the hearing intervention did not significantly slow cognitive decline. The difference between groups was 0.002 standard deviations, with a p-value of .96, according to the 2023 ACHIEVE report in The Lancet. The intervention also involved more than receiving a device. Participants received professional hearing care and ongoing support, so the results should not be interpreted as a simple comparison between buying hearing aids and doing nothing.
Who appeared to benefit?
The overall result hides an important difference between participant groups. In a prespecified subgroup drawn from a cardiovascular health study, the hearing intervention reduced cognitive change by 48% over three years. It had no effect in the healthier volunteer group, according to Johns Hopkins' ACHIEVE findings. A later analysis examined each participant's predicted risk of cognitive decline.
Among those in the highest-risk quarter, decline was 58.1% slower with the hearing intervention. The effect was not spread evenly across the full trial population, as reported in Alzheimer's & Dementia. These findings suggest targeted promise rather than universal protection. Hearing treatment may matter most for older adults who already have several factors associated with cognitive decline, but the trial does not establish that hearing aids prevent Alzheimer's disease.
Why hearing and brain health are connected—but not equivalent
Unaddressed hearing loss is associated with faster cognitive decline and greater dementia risk. An association, however, cannot show that hearing loss causes dementia or that correcting it prevents Alzheimer's. Hearing treatment could still offer meaningful benefits.
Better communication may make conversations and daily activities easier, whether or not it changes a person's long-term dementia risk. The World Health Organization's 2026 guidance places hearing aids within a broader risk-reduction approach. That approach also includes physical activity, social engagement, and management of hypertension, diabetes, and cholesterol. Hearing care should therefore be one part of brain-health planning, not a stand-alone preventive treatment.
What should someone with hearing difficulty do now?
Adults who struggle to hear should seek assessment and treatment for present-day communication and daily-function benefits. They do not need to wait for researchers to settle the Alzheimer's question.
A practical path is: In the United States, over-the-counter hearing aids are intended only for adults who perceive mild-to-moderate hearing loss. Severe hearing loss calls for professional care, according to current FDA consumer guidance.
- Note where hearing problems occur, such as conversations or everyday activities.
- Arrange a hearing assessment and discuss suitable treatment.
- Ask what fitting, follow-up, and audiologic support are included.
- Treat hearing care as one part of a broader plan for reducing dementia risk.
What evidence is still missing?
Researchers need longer follow-up and disease-based outcomes. The original ACHIEVE trial tracked cognitive change for three years, not new diagnoses of Alzheimer's disease or other dementias.
The active ACHIEVE Brain Health Follow-Up study is examining whether participants develop mild cognitive impairment or dementia after the original randomized intervention. Until those results are available, "may slow cognitive decline in some higher-risk adults" is more accurate than "prevents Alzheimer's.".
